John Mendelsohn, president of the MD Anderson Cancer Center, discusses with ONCOLOGY the recent advances in using a “systems approach” in oncology and how he believes this will affect outcomes in the future.
Videos
In this video interview, Joseph Connors gives an overview of the results presented here at ASCO of the phase II trial of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, and discusses the most intriguing work currently being done with novel agents used to treat relapsed or refractory Hodgkin lymphoma.
Dr. Brenner discusses the role of chemopreventives, biomarkers, and early detection for cancer prevention.
Dr. Leachman discusses the use of genetic testing for cancer patients.
Dr. Correa discusses her work on brain tumors and genetics, and their contribution to adverse side effects.
Dr. Loprinzi discusses the role of diet and exercise in cancer prevention.
Advertisement
Advertisement
Trending on CancerNetwork
1
Emactuzumab Responses Yield Statistical Significance in Tenosynovial Giant Cell Tumor
2
Pirtobrutinib Triplet Boosts PFS in Relapsed/Refractory CLL/SLL Trial
3
Outlining Precision Prognosis and Therapy Tools Across the NET Spectrum
4
Tisotumab Vedotin Combo Elicits Responses in Frontline Recurrent Cervical Cancer
5